Scott Henry, CFA

Managing Director, Senior Research Analyst & Head of Pharmaceuticals Research



Scott Henry a Managing Director, Senior Research Analyst and Head of Pharmaceuticals Research covering the Specialty Pharmaceuticals sector.  Mr. Henry came to Roth Capital directly from Oppenheimer where he led coverage of the US pharmaceutical sector, and he brings ~12 years of sell-side experience. Mr. Henry has also been affiliated with Thomas Weisel Partners, ABN AMRO, and Leerink Swann & Co.

Mr. Henry's universe included specialty pharmaceuticals, large-cap pharmaceuticals, and biotech, along with selective medical device names. Among awards, Scott was ranked #2 in the Wall Street Journal Best on the Street Stock picking survey in 2010, #3 on the Forbes/Zacks Investment Research Best Analysts, for the Drugs category in 2010, and #3 in the pharmaceutical sector by for earnings estimate accuracy during 2007. His investment views have been cited in the Wall Street Journal and the New York Times and he has made frequent appearances on CNBC, CBS Marketwatch, and Bloomberg.

Mr. Henry attended the University of Rhode Island and received an M.B.A. with distinction from Cornell University.


Joined Roth

February 2008

Sector Focus



University of Rhode Island & Cornell University


Oppenheimer, Thomas Weisel Partners, ABN AMRO, and Leerink Swann & Co.


Drugs Industry No. 3 “Best Brokerage Analyst” Award Forbes/Zacks 2010

Pharmaceuticals No. 2 Master Stock Picker “Best on the Street” Award The Wall Street Journal 2010

Pharmaceuticals No. 3 Top Earnings Estimator Award, FT StarMine 2011

Pharmaceuticals No. 2 Top Stock Picker Award, Thompson Reuters StarMine 2014